Pachman LM, Nolan BE, DeRanieri D, Khojah AM. Juvenile Dermatomyositis: New clues to diagnosis and therapy. Curr Treatm Opt Rheumatol. 2021;7(1):39–62.

Article  PubMed  PubMed Central  Google Scholar 

Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300–5.

Article  PubMed  Google Scholar 

Pachman LM, Khojah AM. Advances in Juvenile Dermatomyositis: Myositis specific antibodies aid in understanding Disease Heterogeneity. J Pediatr. 2018;195:16–27.

Article  PubMed  PubMed Central  Google Scholar 

Costin C, Morgan G, Khojah A, Klein-Gitelman M, Pachman LM. Lower NK cell numbers in children with untreated juvenile Dermatomyositis during the COVID-19 pandemic. Clin Immunol Commun. 2023.

Khojah A, Liu V, Savani SI, Morgan G, Shore R, Bellm J, et al. Association of p155/140 Autoantibody with loss of Nailfold Capillaries but not generalized Lipodystrophy: a study of ninety-six children with Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). 2022;74(7):1065–9.

Article  CAS  PubMed  Google Scholar 

Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004;31(8):1644–9.

PubMed  Google Scholar 

Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated Disease in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;58(2):571–6.

Article  PubMed  PubMed Central  Google Scholar 

Gibbs EKA, Morgan G, Ehwerhemuepha L, Pachman LM. The Von Willebrand Factor Antigen reflects the Juvenile Dermatomyositis Disease activity score. Biomedicines. 2023;11(2):552.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;59(2):222–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saini I, Kalaivani M, Kabra SK. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int. 2016;36(7):961–5.

Article  CAS  Google Scholar 

Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Med (Baltim). 2008;87(2):70–86.

Article  Google Scholar 

Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.

Article  CAS  Google Scholar 

Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.

Article  CAS  PubMed  Google Scholar 

Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003;49(1):7–15.

Article  PubMed  Google Scholar 

Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and Patient/Parent global activity, manual muscle testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity score (DAS), short form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), Myositis Functional Index-2 (FI-2), Myositis activities Profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), cutaneous Assessment Tool (CAT), Dermatomyositis skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(0 11):118–57.

Google Scholar 

Pachman LM, Morgan G, Klein-Gitelman MS, Ahsan N, Khojah A. Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: an indicator of Disease activity. Pediatr Rheumatol. 2023;21(1):118.

Article  Google Scholar 

Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, et al. Nailfold capillary density is importantly associated over time with muscle and Skin Disease activity in juvenile dermatomyositis. Rheumatology (Oxford). 2011;50(5):885–93.

Article  Google Scholar 

Lim LS, Pullenayegum E, Moineddin R, Gladman DD, Silverman ED, Feldman BM. Methods for analyzing observational longitudinal prognosis studies for rheumatic Diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatr Rheumatol Online J. 2017;15(1):18.

Article  PubMed Central  Google Scholar 

Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19(6):343–62.

Article  PubMed  PubMed Central  Google Scholar 

Kishi T, Chipman J, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, et al. Endothelial activation markers as Disease activity and damage measures in Juvenile Dermatomyositis. J Rheumatol. 2020;47(7):1011–8.

Article  CAS  PubMed  Google Scholar 

Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, et al. Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. Rheumatology (Oxford). 2018;57(4):671–6.

Article  CAS  PubMed  Google Scholar 

Yu HH, Chang HM, Chiu CJ, Yang YH, Lee JH, Wang LC, et al. Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis. J Microbiol Immunol Infect. 2016;49(2):264–70.

Article  CAS  PubMed  Google Scholar 

Bukhari A, Khojah A, Marin W, Khramtsov A, Khramtsova G, Costin C, et al. Increased otoferlin expression in B cells is Associated with muscle weakness in untreated juvenile dermatomyositis: a pilot study. Int J Mol Sci. 2023;24(13):10553.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ochfeld E, Hans V, Marin W, Ahsan N, Morgan G, Pachman LM, et al. Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study. BMC Rheumatol. 2022;6(1):36.

Article  PubMed  PubMed Central  Google Scholar 

Khojah A, Morgan G, Pachman LM. Clues to Disease Activity in Juvenile Dermatomyositis: neopterin and other biomarkers. Diagnostics (Basel). 2021;12(1).

McLellan K, Papadopoulou C. Update on biomarkers of Vasculopathy in Juvenile and Adult Myositis. Curr Rheumatol Rep. 2022;24(7):227–37.

Article  CAS  PubMed  Google Scholar 

Bloom BJ, Miller LC, Blier PR. Soluble adhesion molecules in pediatric rheumatic Diseases. J Rheumatol. 2002;29(4):832–6.

CAS  PubMed  Google Scholar 

Wang A, Khojah A, Morgan G, Pachman LM. Nailfold capillary dropout precedes the presentation of Pneumatosis Intestinalis and micro-perforation in juvenile dermatomyositis. Clin Immunol Commun. 2023;3:74–6.

Article  CAS  Google Scholar